Shepherd K M, Sage R E
Res Commun Chem Pathol Pharmacol. 1986 Dec;54(3):367-78.
The ability of a number of DNA binding drugs to block the action of selected restriction enzymes has been used to determine the nucleotide base binding preference of these drugs. The three alkylating agents studied all displayed guanine-cytosine (G-C) base binding preference which accords with previous results for cis-DDP and with the preferred sites of alkylation being the N7 and O6 of guanine bases. Adriamycin was markedly more reactive in this assay system compared to the alkylating drugs and in contrast to these drugs showed an adenine-thymine (A-T) base binding preference.
许多DNA结合药物阻断特定限制酶作用的能力已被用于确定这些药物的核苷酸碱基结合偏好。所研究的三种烷基化剂均表现出鸟嘌呤-胞嘧啶（G-C）碱基结合偏好，这与顺铂之前的结果一致，且烷基化的优先位点是鸟嘌呤碱基的N7和O6。与烷基化药物相比，阿霉素在该检测系统中反应明显更活跃，并且与这些药物不同，它表现出腺嘌呤-胸腺嘧啶（A-T）碱基结合偏好。
